Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01057342|
Recruitment Status : Completed
First Posted : January 27, 2010
Last Update Posted : April 10, 2013
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Dimethylxanthenone acetic acid may stop the growth of small cell lung cancer by blocking blood flow to the tumor. Giving paclitaxel and carboplatin together with dimethylxanthenone acetic acid may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects of giving paclitaxel and carboplatin together with dimethylxanthenone acetic acid and to see how well they work in treating patients with extensive-stage small cell lung cancer.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Drug: carboplatin Drug: paclitaxel Drug: vadimezan||Phase 2|
- To assess the 24-week (6 months) progression-free survival of patients with extensive stage small cell lung cancer treated with paclitaxel, carboplatin, and dimethylxanthenone acetic acid.
- To assess efficacy and safety of this regimen in these patients.
- To evaluate predictive molecular markers for gene expression analyses, serum proteomics, and pharmacogenomics. (exploratory)
OUTLINE: This is a multicenter study.
Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and dimethylxanthenone acetic acid IV over 20 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Blood and tissue samples may be collected periodically for predictive molecular markers for gene expression analysis, plasma proteomics, and pharmacogenomics.
After completion of study treatment, patients are followed every 6 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Carboplatin and Paclitaxel Plus ASA404 as First Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||May 2011|
|Actual Study Completion Date :||July 2012|
|Experimental: Paclitaxel, Carboplatin, ASA404||
AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
Other Name: Paraplatin
175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
Other Name: Abraxane Taxol
1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
Other Name: ASA404
- Progression-free survival rate [ Time Frame: at 24 weeks (6 months) ]
The status of progression free survival at 24 weeks (+/- 2 weeks) from trial registration will be assessed. A PFS event is defined as (whichever occurs first):
- Relapse or progression assessed according to the RECIST 1.1 criteria (Appendix 1)
- Death of any cause.
- Adverse events by NCI CTCAE v3.0 [ Time Frame: until 30 days after trial therapy end ]
- Best objective response OR complete or partial response according to RECIST 1.1 [ Time Frame: whilst receiving the trial therapy ]
- Time to progression [ Time Frame: Defined as the time from registration until documented Small-cell Lung Cancer (SCLC) progression or death as a result of SCLC. ]
- Overall survival [ Time Frame: Time from registration until death as a result of any cause. ]
- One-year survival rate [ Time Frame: at 1 year ]Patients alive one year after trial registration
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01057342
|Saint Claraspital AG|
|Basel, Switzerland, CH-4016|
|Basel, Switzerland, CH-4031|
|Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni|
|Bellinzona, Switzerland, CH-6500|
|Bern, Switzerland, CH-3010|
|Biel, Switzerland, CH-2501|
|Centre Hospitalier Universitaire Vaudois|
|Lausanne, Switzerland, CH-1011|
|Olten, Switzerland, CH-4600|
|Schaffhausen, Switzerland, CH-8200|
|Kantonsspital - St. Gallen|
|St. Gallen, Switzerland, CH-9007|
|Thun, Switzerland, 3600|
|Winterthur, Switzerland, CH-8400|
|Zurich, Switzerland, CH-8032|
|Study Chair:||Martin Frueh, MD||Cantonal Hospital of St. Gallen|
|Study Chair:||Miklos Pless, MD||Kantonsspital Winterthur KSW|
|Study Chair:||Oliver Gautschi, MD||University Hospital Inselspital, Berne|